Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Lacouture

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The British Journal of Dermatology|December 13, 2016
Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitorsA Zarbo, V R Belum, V Sibaud, et al.
Clinical Pharmacology and Therapeutics|December 17, 2009
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertensionM Gomberg-Maitland, M L Maitland, R J Barst, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2016
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancerM E Lacouture, D M Keefe, S Sonis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2016
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorV R Belum, B Benhuri, M A Postow, et al.
Breast Cancer Research and Treatment|July 5, 2008
Analysis of dermatologic events in patients with cancer treated with lapatinibM E Lacouture, S M Laabs, M Koehler, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 20, 2019
Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective studyD M Barrios, G S Phillips, A Freites-Martinez, et al.
ESMO Open|January 28, 2026
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancerK L Jhaveri, N M Iyengar, N C Turner, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
Journal for Immunotherapy of Cancer|November 23, 2017
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupI Puzanov, A Diab, K Abdallah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The British Journal of Dermatology|December 13, 2016
Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitorsA Zarbo, V R Belum, V Sibaud, et al.
Clinical Pharmacology and Therapeutics|December 17, 2009
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertensionM Gomberg-Maitland, M L Maitland, R J Barst, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2016
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancerM E Lacouture, D M Keefe, S Sonis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2016
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorV R Belum, B Benhuri, M A Postow, et al.
Breast Cancer Research and Treatment|July 5, 2008
Analysis of dermatologic events in patients with cancer treated with lapatinibM E Lacouture, S M Laabs, M Koehler, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 20, 2019
Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective studyD M Barrios, G S Phillips, A Freites-Martinez, et al.
ESMO Open|January 28, 2026
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancerK L Jhaveri, N M Iyengar, N C Turner, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
Journal for Immunotherapy of Cancer|November 23, 2017
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupI Puzanov, A Diab, K Abdallah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2021
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapiesD M Barrios, G S Phillips, A N Geisler, et al.
Pageof 3